Modified yersinia
Modified yersinia
Search
Oxidase Inhibitor
Oxidase Inhibitor
SGLT2 inhibitor
BI 765845: Heart disease modulator | Myocardial infarction
BI 765845: Heart disease modulator | Myocardial infarction
KISIMA® Cancer Vaccine
KISIMA® Cancer Vaccine
Side Effects Reporting
Side Effects Reporting
Cat diabetes infographic with key facts and figures
786214027-001_BI_Speso_NS_Infographic_Unmet-Need_2024_cc04.pdf
Brigimadlin (BI 907828): MDM2-p53 antagonist | NSCLC
Brigimadlin (BI 907828): MDM2-p53 antagonist | NSCLC
Second generation STING agonist
Second generation STING agonist
BI 1291583: CatC Inhibitor
BI 1291583: CatC Inhibitor
Ion channel inhibitor
STING agonist (2nd generation)
KRAS multi-inhibitor
Modified yersinia
Semintra®
For the management of chronic kidney disease and hypertension in cats.
October 2024 Pipeline
Lysophospholipase inhibitor
Lysophospholipase inhibitor
Lysophospholipase inhibitor
Vicadrostat (BI 690517) + empagliflozin
Vicadrostat (BI 690517) + empagliflozin
Vicadrostat (BI 690517) + empagliflozin
Vicadrostat (BI 690517) + empagliflozin
MedInfo Mailbox List.pdf
Fornovo
With its production facilities, Fornovo San Giovanni constitutes an important site for the production of core active pharmaceutical ingredients for both Human Pharma and Animal Health.
Nutrition
People with cancer discuss the benefits she experienced through making dietary changes whilst undergoing cancer treatment.
More Potential Overview
Working at the intersection of human and animal health, we have unique opportunities to positively impact vulnerable populations.